1. Cancer Statistics, 2021;Siegel,2021
2. FDA Approves First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer | FDA.
3. FDA approves new diagnostic imaging agent to detect recurrent prostate cancer | FDA cited 2021]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-diagnostic-imaging-agent-detect-recurrent-prostate-cancer
4. FDA Approves 18F-DCFPyL as First PSMA PET Imaging Agent Available for Prostate Cancer. Available from: https://www.cancernetwork.com/view/fda-approves-18f-dcfpyl-as-first-psma-pet-imaging-agent-available-for-prostate-cancer
5. Prediction of time to hormonal treatment failure in metastatic castration-sensitive prostate cancer with 18F-FDG PET/CT;Jadvar;Journal of Nuclear Medicine . Society of Nuclear Medicine Inc.,2019